BACKGROUND: Combination antiretroviral therapy (cART) is associated with lipodystrophy (lipoatrophy and lipoaccumulation) and several metabolic abnormalities that together can contribute to an increased cardiovascular risk. The aim of this study was to evaluate the prevalence of obesity in patients on cART according to the presence of clinical lipodystrophy (CL) and to analyze factors associated with obesity. METHODS: We evaluated 368 HIV-infected adults on cART. RESULTS: CL was present in 59.0%. Independently of gender, patients with CL were more frequently underweight [5.7% (21/368)] and of normal weight [47.3% (174/368)], and less frequently overweight [33.2% (122/368)] or obese [13.9% (51/368)]. Mean body mass index was higher in patients with abdominal prominence regardless of the presence of clinical lipoatrophy. Patients with CL had lower waist circumference, higher waist/hip and fat mass ratio and lower total and subcutaneous fat, without significant difference in visceral fat but with a higher visceral/subcutaneous fat ratio, as evaluated by CT at abdominal level. CL was significantly less frequent in overweight [odds ratio (OR)=0.21, 95% confidence interval (CI): 0.05-0.92] and obese (OR=0.05, 95%CI: 0.01-0.26) patients, when compared to underweight ones, independent of age, gender, duration of infection, cART regimen, virological suppression, and HIV-infection risk factor. CONCLUSIONS: Being overweight or obese is highly prevalent in HIV-infected patients on cART. Patients with CL were more frequently under- or normal weight, and less frequently overweight or obese. Obesity is a condition that should be considered in HIV patients on cART.
BACKGROUND: Combination antiretroviral therapy (cART) is associated with lipodystrophy (lipoatrophy and lipoaccumulation) and several metabolic abnormalities that together can contribute to an increased cardiovascular risk. The aim of this study was to evaluate the prevalence of obesity in patients on cART according to the presence of clinical lipodystrophy (CL) and to analyze factors associated with obesity. METHODS: We evaluated 368 HIV-infected adults on cART. RESULTS: CL was present in 59.0%. Independently of gender, patients with CL were more frequently underweight [5.7% (21/368)] and of normal weight [47.3% (174/368)], and less frequently overweight [33.2% (122/368)] or obese [13.9% (51/368)]. Mean body mass index was higher in patients with abdominal prominence regardless of the presence of clinical lipoatrophy. Patients with CL had lower waist circumference, higher waist/hip and fat mass ratio and lower total and subcutaneous fat, without significant difference in visceral fat but with a higher visceral/subcutaneous fat ratio, as evaluated by CT at abdominal level. CL was significantly less frequent in overweight [odds ratio (OR)=0.21, 95% confidence interval (CI): 0.05-0.92] and obese (OR=0.05, 95%CI: 0.01-0.26) patients, when compared to underweight ones, independent of age, gender, duration of infection, cART regimen, virological suppression, and HIV-infection risk factor. CONCLUSIONS: Being overweight or obese is highly prevalent in HIV-infectedpatients on cART. Patients with CL were more frequently under- or normal weight, and less frequently overweight or obese. Obesity is a condition that should be considered in HIVpatients on cART.
Authors: E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo Journal: Ann Intern Med Date: 2001-07-03 Impact factor: 25.391
Authors: E Bonnet; C Delpierre; A Sommet; F Marion-Latard; R Hervé; C Aquilina; E Labau; M Obadia; B Marchou; P Massip; B Perret; J Bernard Journal: J Clin Densitom Date: 2005 Impact factor: 2.963
Authors: S Belo; A C Santos; A Madureira; J Pereira; A Sarmento; D Carvalho; P Freitas Journal: J Endocrinol Invest Date: 2015-02-27 Impact factor: 4.256
Authors: Claire L McCormick; Arianne M Francis; Kim Iliffe; Helen Webb; Catherine J Douch; Mark Pakianathan; Derek C Macallan Journal: Front Immunol Date: 2014-11-13 Impact factor: 7.561
Authors: Marcelo N Pedro; Guilherme Z Rocha; Dioze Guadagnini; Andrey Santos; Daniela O Magro; Heloisa B Assalin; Alexandre G Oliveira; Rogerio de Jesus Pedro; Mario J A Saad Journal: Front Endocrinol (Lausanne) Date: 2018-09-05 Impact factor: 5.555
Authors: Mark E Pepin; Lindsey E Padgett; Ruth E McDowell; Ashley R Burg; Manoja K Brahma; Cassie Holleman; Teayoun Kim; David Crossman; Olaf Kutsch; Hubert M Tse; Adam R Wende; Kirk M Habegger Journal: Mol Metab Date: 2018-04-20 Impact factor: 7.422
Authors: Sonia Zicari; Libera Sessa; Nicola Cotugno; Alessandra Ruggiero; Elena Morrocchi; Carlo Concato; Salvatore Rocca; Paola Zangari; Emma C Manno; Paolo Palma Journal: Viruses Date: 2019-02-27 Impact factor: 5.048
Authors: Paula Freitas; Davide Carvalho; Ana Cristina Santos; Joana Mesquita; Maria João Matos; Antonio Jose Madureira; Esteban Martinez; António Sarmento; José Luís Medina Journal: BMC Infect Dis Date: 2012-08-06 Impact factor: 3.090
Authors: Sherly George; Colm Bergin; Susan Clarke; Grainne Courtney; Mary B Codd Journal: Health Qual Life Outcomes Date: 2016-08-05 Impact factor: 3.186